ONCY and ONC Related Headlines
Go Back- Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
- Oncolytics Biotech shareholders elect eight directors at annual meeting
- Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
- Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
- Oncolytics Biotech to delist from Toronto Stock Exchange on August 22
- Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
- Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
- Oncolytics plans FDA talks for pancreatic cancer drug trial
- Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
- Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
- Oncolytics Biotech regains compliance with NASDAQ minimum bid price rule
- Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
- Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
- Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
- Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
- Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
- Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
ONCY and ONC Related Press Releases
Go Back- Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
- Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
- Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
- Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
- Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
- Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
- Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
- Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
- Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
- Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
- Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
- Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
- Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
ONCY and ONC Related SEC Filings
Go Back- Form F-3 ONCOLYTICS BIOTECH INC
- Form 6-K ONCOLYTICS BIOTECH INC For: Aug 11
- Form 6-K ONCOLYTICS BIOTECH INC For: Aug 08
- Form 6-K ONCOLYTICS BIOTECH INC For: Aug 08
- Form 6-K ONCOLYTICS BIOTECH INC For: Jun 30
- Form 6-K ONCOLYTICS BIOTECH INC For: Aug 08
- Form 6-K ONCOLYTICS BIOTECH INC For: Aug 05
- Form 6-K ONCOLYTICS BIOTECH INC For: Jul 29
- Form 6-K ONCOLYTICS BIOTECH INC For: Jul 23
- Form 6-K ONCOLYTICS BIOTECH INC For: Jul 22
- Form 6-K ONCOLYTICS BIOTECH INC For: Jul 16
- Form 6-K ONCOLYTICS BIOTECH INC For: Jul 10
- Form 6-K ONCOLYTICS BIOTECH INC For: Jul 08
- Form 6-K ONCOLYTICS BIOTECH INC For: Jul 08
- Form 6-K ONCOLYTICS BIOTECH INC For: Jun 30
- Form 6-K ONCOLYTICS BIOTECH INC For: Jun 11
